Back to results
US 12,678,408 B2Granted
Pharmaceutical formulations comprising tenofovir alafenamide and emtricitabine
AssigneeGilead Sciences, Inc.
InventorsJoanna M. Koziara, Scott McCallister
Life of this patent
Estimating the term…
Abstract
The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.
Claims29
A tablet, consisting of:
- (a) 25 mg tenofovir alafenamide, or a pharmaceutically acceptable salt thereof, calculated as tenofovir alafenamide free base;
- (b) 200 mg emtricitabine, or a pharmaceutically acceptable salt thereof, calculated as emtricitabine free base;
- (c) excipients selected from:
- (i) microcrystalline cellulose or lactose;
- (ii) croscarmellose sodium or crospovidone;
- and
- (iii) magnesium stearate;
- and
- (d) coating;
- wherein the tablet contains only two active pharmaceutical ingredients:
- tenofovir alafenamide, or a pharmaceutically acceptable salt thereof, and emtricitabine, or a pharmaceutically acceptable salt thereof;
- and
- wherein the tablet has a total weight of less than 600 mg.
10 more elements
A tablet, consisting of:
- (a) a fumarate salt of tenofovir alafenamide, equivalent to 25 mg tenofovir alafenamide free base;
- (b) 200 mg emtricitabine;
- (c) excipients selected from:
- (i) microcrystalline cellulose or lactose;
- (ii) croscarmellose sodium or crospovidone;
- and
- (iii) magnesium stearate;
- and
- (d) a coating;
- wherein the tablet contains only two active pharmaceutical ingredients:
- the fumarate salt of tenofovir alafenamide, and emtricitabine;
- and
- wherein the tablet has a total weight between 300 mg and 500 mg.
10 more elements
A tablet, consisting of:
- (a) 25 mg tenofovir alafenamide, or a fumarate salt thereof, calculated as tenofovir alafenamide free base;
- (b) 200 mg emtricitabine, or a pharmaceutically acceptable salt thereof, calculated as emtricitabine free base;
- (c) excipients selected from:
- (i) microcrystalline cellulose, lactose, mannitol, or dibasic calcium phosphate;
- (ii) croscarmellose sodium or crospovidone;
- and
- (iii) magnesium stearate;
- and
- (d) a coating;
- wherein the tablet contains only two active pharmaceutical ingredients:
- tenofovir alafenamide, or a fumarate salt thereof, and emtricitabine, or a pharmaceutically acceptable salt thereof;
- and
- wherein the tablet has a total weight of about 450 mg.
10 more elements
A tablet, consisting of:
- (a) a fumarate salt of tenofovir alafenamide, equivalent to 25 mg tenofovir alafenamide free base;
- (b) 200 mg emtricitabine, or a pharmaceutically acceptable salt thereof, calculated as emtricitabine free base;
- (c) excipients selected from:
- (i) microcrystalline cellulose or lactose;
- (ii) croscarmellose sodium or crospovidone;
- and
- (iii) magnesium stearate;
- and
- (d) a coating;
- wherein the tablet contains only two active pharmaceutical ingredients:
- the fumarate salt of tenofovir alafenamide, and emtricitabine, or a pharmaceutically acceptable salt thereof;
- and
- wherein the tablet has a total weight of 350 mg±50 mg.
10 more elements
Dependencies are inferred from the claim text.